Crossmark

The best fit for enzalutamide in metastatic prostate cancer

Crossref DOI link: https://doi.org/10.1038/nrclinonc.2014.128

Published Online: 2014-07-29

Published Print: 2014-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pal, Sumanta K.

Sartor, Oliver
License Information

Text and Data Mining valid from 2014-07-29
More Information

Article History

First Online: 29 July 2014

Competing interests

: S.K.P. has received honoraria from Medivation. O.S. is a consultant for Medivation/Astellas, and a consultant and investigator for Bayer, Dendreon, Janssen, and Sanofi.